Energy
Michael Dell's Son Built a $13 Billion Battery Company by Renting Out Your Backyard
Base Power raised $1B at a $13B valuation to bury US-made batteries in Texas backyards and run them as one giant virtual power plant.
Instantly review
8.0/10★★★★★Cold email platform with unlimited inboxes, warm-up, lead data and AI agents
- Best for
- Founders and small teams running high-volume cold email
- Price
- Free trial · from $47/month
Free: Free trial, no credit card - Platforms
- Web, API
- Made by
- Instantly
What it is
Instantly sends cold email from unlimited connected mailboxes with built-in warm-up and rotation, and sells B2B leads through its SuperSearch credits. AI agents write emails, research prospects and handle replies.
What the AI does
- AI Sales Agent
- AI Reply Agent
- Web Researcher Agent
- Email Writer Agent
- Instantly AI copilot
Pros and cons
- Unlimited mailboxes and warm-up from the cheapest plan
- Lead database and sending in one product
- Polished, easy interface
- Leads and sending are billed separately
- Lead data quality varies by segment
- Personalisation less sophisticated than Lemlist
How it scores
The best all-rounder for cold email at small-team budgets.
Feature checklist · 6 of 9
- Built-in B2B contact database (yes)
- Finds and verifies emails or enriches leads (yes)
- AI writes personalised messages (yes)
- Automated multi-step email sequences (yes)
- LinkedIn steps in sequences (no)
- Calling or dialer (no)
- Inbox warm-up and deliverability tools (yes)
- AI agent that runs outreach end to end (yes)
- Syncs with Salesforce or HubSpot (no)
Alternatives
See all Instantly alternatives, ranked →
- Apollo.io 8.2/10Startups and sales teams that want data and outreach in one affordable tool
- Lemlist 7.9/10Teams that want personalised email plus LinkedIn and calling steps
- Amplemarket 7.4/10Mid-size sales teams that want data, signals and sequences in one tool
- Clay 7.3/10Growth and RevOps teams building highly targeted lists
Apollo.io vs InstantlyInstantly vs LemlistInstantly vs Amplemarket
Sources
▸▸ Instantly in the news
Defense Tech
A Robot-Run Factory Startup Just Raised $1.37 Billion — and Its Valuation Quintupled Since January
Hadrian raised $1.37B at a $7.87B valuation to scale AI-run factories making parts for rockets, subs, and jets — its price tag quintupled since January.
Biotech
A $425,000 Kidney Drug Just Cleared the FDA — and It Hits Two Targets No One Had Hit at Once
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.